drugset / Trial / NCT06752811
Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine.
Timeline
- Start
- 2025-02-05
- Primary completion
- 2027-07-01
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 300 mg/m2 | Intravenous |